Evaluation of the Anti-arthritic, Anti-inflammatory, and Chondroprotective Effect of a Novel Nutritional Formulation in Monoiodoacetate-Induced Osteoarthritis Animal Model

Shallaki, Turmeric, and Ashwagandha are key ingredients commonly incorporated into nutritional formulations for the management of osteoarthritis (OA). This preclinical study aims to evaluate the efficacy of the nutritional Rhumaflex formulation in its antiarthritic, anti-inflammatory, and chondroprotective potential in osteoarthritis. In this study, 32 Wistar rats were evenly allocated to four groups of 8 each. SC and DC groups orally received 1% CMC, while the PC group was given oral Indomethacin (2 mg/kg) in 1% CMC. The test group orally received Rhumaflex (206.46 mg/kg) in 1% CMC over a 28-day period. The study demonstrated that the Rhumaflex treatment group reduced swelling and improved mobility within 7 days of treatment. By day 28, significant anti-inflammatory effects were observed, evidenced by lowered COMP, MMP-13, and TNF-alpha levels. Due to research-backed ingredients, chondroprotective potential and lower degeneration was indicated in the Rhumaflex group compared to controls, suggesting efficacy for regeneration and chondroprotection. Rhumaflex exhibits multifaceted benefits, including anti-arthritic and anti-inflammatory effects, offering a promising alternative, particularly for patients seeking alternatives to conventional treatments. The selective ingredients of the formulation have shown promising effects in promoting joint cartilage regeneration and chondroprotection. While these preclinical results are promising, further clinical trials are underway to confirm these benefits in human subjects and establish long-term safety and efficacy profiles.